FACTORS ASSOCIATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS UTILIZATION IN RHEUMATOID ARTHRITIS PATIENTS

被引：0
|
作者：
Hosseini, R. [1 ]
Brown, L. [1 ]
Rodriguez-Monguio, R. [2 ]
Seoane-Vazquez, E. [1 ]
机构：
[1] Chapman Univ, Sch Pharm, Irvine, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH101
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [21] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [22] IMPACT OF CORTICOSTEROID UTILIZATION ON BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG INITIATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS
    Spivey, C. A.
    Griffith, J.
    Kaplan, C.
    Postlethwaite, A.
    Ganguli, A.
    Wang, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1503 - 1503
  • [23] Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
    Natalia Mena-Vazquez
    Sara Manrique-Arija
    Lucía Yunquera-Romero
    Inmaculada Ureña-Garnica
    Marta Rojas-Gimenez
    Carla Domic
    Francisco Gabriel Jimenez-Nuñez
    Antonio Fernandez-Nebro
    Rheumatology International, 2017, 37 : 1709 - 1718
  • [24] MEDICATION ADHERENCE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A REGISTER STUDY
    Joensuu, J. T.
    Aaltonen, K. J.
    Valleala, H.
    Puolakka, K.
    Yli-Kerttula, T.
    Varjolahti-Lehtinen, T.
    Sokka, T.
    Blom, M.
    Nordstrom, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 882 - 883
  • [25] BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS
    Fedele, A. L.
    Melpignano, F.
    Bruno, D.
    La Ferrara, R.
    D'agostino, M. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 603 - 603
  • [26] Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
    Mena-Vazquez, Natalia
    Manrique-Arija, Sara
    Yunquera-Romero, Lucia
    Urena-Garnica, Inmaculada
    Rojas-Gimenez, Marta
    Domic, Carla
    Gabriel Jimenez-Nunez, Francisco
    Fernandez-Nebro, Antonio
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (10) : 1709 - 1718
  • [27] Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
    Li, Ko-Jen
    Chang, Chia-Li
    Hsin, Chih-Yi
    Tang, Chao-Hsiun
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] TIME TO AND FACTORS ASSOCIATED WITH INITIATION OF BIOLOGICAL THERAPY WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COLOMBIA
    Machado-Alba, J. E.
    Calvo-Torres, L. F.
    Banol-Giraldo, A. M.
    Garcia-Betancurt, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 514 - 514
  • [29] Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Inoue, Mariko
    Kanda, Hiroko
    Tateishi, Shoko
    Fujio, Keishi
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 58 - 63
  • [30] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
12345